Exagen (NASDAQ:XGN) Stock Rating Upgraded by KeyCorp

Key Points

• Exagen has been upgraded to an "overweight" rating by KeyCorp, with a price target of $12.00, indicating a potential upside of 42.01% from its current price.
• The company reported quarterly revenue of $15.50 million, surpassing analyst estimates, but still posted an EPS of ($0.20), consistent with expectations.
• Hedge funds and institutional investors own 75.25% of Exagen's stock, with recent purchases indicating increased interest in the company.

KeyCorp upgraded shares of Exagen (NASDAQ:XGN - Free Report) from a sector weight rating to an overweight rating in a research note issued to investors on Wednesday, Marketbeat Ratings reports. They currently have $12.00 price objective on the stock. KeyCorp also issued estimates for Exagen's Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.60) EPS and FY2026 earnings at ($0.31) EPS.

XGN has been the subject of several other research reports. Craig Hallum assumed coverage on Exagen in a report on Wednesday, July 23rd. They issued a "buy" rating and a $12.00 price objective for the company. BTIG Research reiterated a "buy" rating on shares of Exagen in a research report on Wednesday, May 7th. Cantor Fitzgerald lowered their price objective on shares of Exagen from $8.00 to $7.00 and set an "overweight" rating for the company in a research report on Thursday, May 15th. UBS Group restated an "overweight" rating on shares of Exagen in a research report on Thursday, May 15th. Finally, Canaccord Genuity Group boosted their target price on shares of Exagen from $7.00 to $8.00 and gave the stock a "buy" rating in a research note on Tuesday, May 13th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $11.25.

Exagen Price Performance

Shares of XGN traded up $0.23 on Wednesday, hitting $8.63. The company's stock had a trading volume of 282,684 shares, compared to its average volume of 442,268. The company has a market capitalization of $189.86 million, a PE ratio of -9.70 and a beta of 1.61. The company has a debt-to-equity ratio of 1.06, a current ratio of 4.95 and a quick ratio of 4.95. Exagen has a fifty-two week low of $1.78 and a fifty-two week high of $9.10. The company has a 50 day moving average price of $7.19 and a 200 day moving average price of $5.46.

Exagen (NASDAQ:XGN - Get Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The company reported ($0.18) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.18). Exagen had a negative return on equity of 130.38% and a negative net margin of 28.85%. The firm had revenue of $17.20 million for the quarter, compared to the consensus estimate of $16.25 million. On average, research analysts anticipate that Exagen will post -0.88 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Northern Trust Corp lifted its stake in shares of Exagen by 16.7% during the 4th quarter. Northern Trust Corp now owns 18,375 shares of the company's stock valued at $75,000 after buying an additional 2,630 shares in the last quarter. Huntleigh Advisors Inc. lifted its stake in Exagen by 5.7% in the 2nd quarter. Huntleigh Advisors Inc. now owns 87,861 shares of the company's stock worth $613,000 after purchasing an additional 4,753 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in Exagen in the 1st quarter worth approximately $25,000. Geode Capital Management LLC lifted its stake in Exagen by 11.9% in the 4th quarter. Geode Capital Management LLC now owns 98,057 shares of the company's stock worth $402,000 after purchasing an additional 10,442 shares in the last quarter. Finally, Corient Private Wealth LLC purchased a new stake in Exagen in the 4th quarter worth approximately $45,000. 75.25% of the stock is owned by institutional investors.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).